December 09, 2025

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surge...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post

December 05, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post

December 04, 2025

Why Patients Who Need a Lung Transplant Are Often Referred Too Late

A lung transplant expert explains why many doctors wait too long to get their patients onto a transplant waiting list.

Keck Medicine of USC

November 19, 2025

Project ASCENT: Advancing Lung Cancer Screening in Hispanic Populations

Lung cancer remains the leading cause of cancer mortality in the United States, surpassing the combined deaths of breast, colon and prostate cancers.

Baptist Health South Florida

November 17, 2025

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with...

The ASCO Post

November 14, 2025

SABR May Be Comparable to Surgery for Early-Stage NSCLC

Stereotactic ablative radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), accordin...

The ASCO Post

November 11, 2025

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Osimertinib in combination with local consolidative therapy of radiation and/or surgery led to a significant extension of progression-free survival for patients with EGFR-mutant metastatic non–small c...

The ASCO Post